LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

Home・Akcijų sąrašas・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Atidarymo kaina

16.66 0.12

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.46

Max

16.73

Pagrindiniai rodikliai
By Trading Economics
Pajamos	35M 9.5M
Pardavimai	35M 94M
Pelnas, tenkantis vienai akcijai	0.06
Pelno marža	10.158
Darbuotojai	619
EBITDA	35M 17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+23.35% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 2.7B
Ankstesnė atidarymo kaina	16.54
Ankstesnė uždarymo kaina	16.66

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

8.81 / 10.18 Palaikymas ir pasipriešinimas

Adaptive Biotechnologies Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025-12-28 23:57; UTC

Uždarbis

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

2025-12-28 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-28 23:48; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-28 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2025-12-28 10:30; UTC

Įsigijimai, susijungimai, perėmimai

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

2025-12-26 20:22; UTC

Rinkos pokalbiai

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025-12-26 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025-12-26 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025-12-26 17:45; UTC

Rinkos pokalbiai

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025-12-26 15:52; UTC

Rinkos pokalbiai

Oil Futures Turn Lower After Steady Start -- Market Talk

2025-12-26 14:58; UTC

Rinkos pokalbiai

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025-12-26 14:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025-12-26 14:28; UTC

Rinkos pokalbiai

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025-12-26 13:47; UTC

Rinkos pokalbiai

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025-12-26 07:22; UTC

Rinkos pokalbiai

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025-12-26 05:03; UTC

Rinkos pokalbiai

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025-12-26 01:39; UTC

Rinkos pokalbiai

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025-12-26 01:14; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025-12-26 00:34; UTC

Rinkos pokalbiai

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025-12-26 00:15; UTC

Rinkos pokalbiai

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025-12-25 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025-12-25 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025-12-25 00:20; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025-12-24 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025-12-24 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Akcijų palyginimas

Kainos pokytis

Adaptive Biotechnologies Corp Prognozė

Kainos tikslas

By TipRanks

23.35% į viršų

12 mėnesių prognozė

Vidutinis 20.6 USD 23.35%

Aukščiausias 22 USD

Žemiausias 20 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Adaptive Biotechnologies Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Adaptive Biotechnologies Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.81 / 10.18Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.